Emergent BioSolutions Inc.
做多
已更新

EBS: It's pretty bad when you underperform TNXP

100
Considering TNXP does... well... nothing, EBS underperforming TNXP is disappointing. Still holding and will continue to buy shares if SP falls back into the gray area at $25-$32. Monthly hammer + continuation off a high volume node + 2.618 fib should indicate a trend reversal.
EBS was never a "squeeze" play because it's already worth a billion dollars. Additionally, I don't believe monkey pox is a serious pandemic regardless of what WHO says. EBS still has a pipeline of drugs that generates revenue and profit. With or without Monkey Pox, EBS should see $50-$60 (fibs) imo.
注释
Terrible miss on earnings with lowered guidance. More accumulation here.

免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。